Format

Send to

Choose Destination
Curr Atheroscler Rep. 2017 Sep 25;19(11):43. doi: 10.1007/s11883-017-0679-5.

Pharmacogenetics of Lipid-Lowering Agents: an Update Review on Genotype-Dependent Effects of HDL-Targetingand Statin Therapies.

Author information

1
Department of Medicine, Montreal Heart Institute, 5000 Belanger St, Montreal, Quebec, H1T 1C8, Canada.
2
Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Strasbourg, France.
3
Faculté de Médecine, Université de Montréal, Montréal, Québec, Canada.
4
Department of Medicine, Montreal Heart Institute, 5000 Belanger St, Montreal, Quebec, H1T 1C8, Canada. jean-claude.tardif@icm-mhi.org.
5
Faculté de Médecine, Université de Montréal, Montréal, Québec, Canada. jean-claude.tardif@icm-mhi.org.

Abstract

PURPOSE OF REVIEW:

High-density lipoproteins (HDL) are involved in reverse cholesterol transport. Results from randomized trials of HDL-targeting therapies, including cholesteryl ester transfer protein (CETP) inhibitors, have shown a lack of benefit in unsegmented populations. These observations could be explained by inter-individual variability of clinical responses to such agents depending on the patients' genotypes. In parallel, although lowering of LDL cholesterol (LDL-c) with statin therapy reduces the risk of vascular events in a wide range of individuals, inter-individual variability exists with regard to LDL-c-lowering response as well as efficacy in reducing major cardiovascular events.

RECENT FINDINGS:

Pharmacogenomic analyses were performed in the dal-OUTCOMES and dal-PLAQUE-2 studies. Beneficial and concordant results were observed in patients with the favorable genotype when treated with the CETP inhibitor dalcetrapib. Similarly, previous studies revealed genetic variants associated with differential LDL-c response to statin therapy. In this review, we discuss the pharmacogenetic determinants of HDL-targeting and statin therapy responses in light of the latest available published data, and their potential therapeutic applications.

KEYWORDS:

Cardiovascular disease; Cholesteryl ester transfer protein (CETP) inhibitors; High-density lipoproteins (HDL); Pharmacogenetics; Statins

PMID:
28944433
DOI:
10.1007/s11883-017-0679-5
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center